Libeo 10 mg Chewable Tablets for Dogs

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Active ingredient:

Furosemide

Available from:

Ceva Animal Health Ltd

ATC code:

QC03CA01

INN (International Name):

Furosemide

Pharmaceutical form:

Chewable tablet

Prescription type:

POM-V - Prescription Only Medicine – Veterinarian

Therapeutic group:

Dogs

Therapeutic area:

Cardio Vascular diuretic

Authorization status:

Authorized

Authorization date:

2014-03-04

Summary of Product characteristics

Revised: October 2022
AN: 01670/2022
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
LIBEO 10 MG CHEWABLE TABLETS FOR DOGS
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One tablet of 330 mg contains:
ACTIVE SUBSTANCE:
Furosemide .........................................................10
mg
EXCIPIENT(S):
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Chewable tablet
Clover shape beige tablet. The tablets can be divided into equal
quarters
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment of ascites and oedema, particularly associated with cardiac
insufficiency
4.3
CONTRAINDICATIONS
Do not use in dogs suffering from hypovolaemia, hypotension or
dehydration.
Do not use in cases of renal failure with anuria.
Do not use in cases of electrolyte deficiency.
Do not use in cases of hypersensitivity to furosemide, sulfonamides or
any of
the excipients.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Therapeutic efficacy may be impaired by increased intake of drinking
water.
Where the animal’s condition permits, water intake should be
restricted to
physiologically normal levels during treatment.
Revised: October 2022
AN: 01670/2022
Page 2 of 6
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
As the tablets are flavoured, they should be stored in a safe place
out of the
reach of animals.
Furosemide should be used with caution in case of pre-existing
electrolyte
and/or water imbalance, impaired hepatic function (may precipitate
hepatic
coma) and diabetes mellitus. In case of prolonged treatment, hydration
status
and serum electrolytes should be monitored frequently.
1-2 days before and after commencement of treatment with diuretics and
ACE
inhibitors renal function and hydration status should be monitored.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY MEDICINAL PRODUCT TO ANIMALS
People with known hypersensitivity to furosemide should avoid contact